Trade

with

Arena Pharmaceuticals Inc
(NASDAQ: ARNA)
AdChoices
4.17
+0.16
+3.99%
After Hours :
4.14
-0.03
-0.72%

Open

4.00

Previous Close

4.01

Volume (Avg)

2.86M (4.45M)

Day's Range

3.97-4.18

52Wk Range

3.26-7.97

Market Cap.

916.72M

Dividend Rate ( Yield )

-

Beta

-0.32

Shares Outstanding

219.84M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 81.39M

    • Net Income

    • -19.43M

    • Market Cap.

    • 916.72M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -196.69

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -0.32

    • Forward P/E

    • -

    • Price/Sales

    • 30.77

    • Price/Book Value

    • 8.91

    • Price/Cash flow

    • -158.73

      • EBITDA

      • -4.14M

      • Return on Capital %

      • -19.08

      • Return on Equity %

      • -51.31

      • Return on Assets %

      • -19.08

      • Book Value/Share

      • 0.47

      • Shares Outstanding

      • 219.84M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -0.45

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -81.40

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -81.30

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 52.68

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 80.45

            • 82.75

            • Pre-Tax Margin

            • -196.69

            • 39.38

            • Net Profit Margin

            • -196.69

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 61.60

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -689.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.68

              • 0.76

              • Current Ratio

              • 3.98

              • 2.92

              • Quick Ratio

              • 3.69

              • 2.35

              • Interest Coverage

              • -7.34

              • 38.02

              • Leverage Ratio

              • 3.25

              • 2.21

              • Book Value/Share

              • 0.47

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -15.63

                • 238.10

                • P/E Ratio 5-Year High

                • -50.59

                • 634.30

                • P/E Ratio 5-Year Low

                • -4.53

                • 124.82

                • Price/Sales Ratio

                • 30.77

                • 8.94

                • Price/Book Value

                • 8.91

                • 8.12

                • Price/Cash Flow Ratio

                • -158.73

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -51.31

                    (-149.80)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -19.08

                    (-43.00)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -27.55

                    (-49.40)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 0.59

                  • 1.48

                  • Asset Turnover

                  • 0.10

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -22.94M
                  Operating Margin
                  -28.18
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -158.73
                  Ownership

                  Institutional Ownership

                  46.77%

                  Top 10 Institutions

                  36.50%

                  Mutual Fund Ownership

                  26.21%

                  Float

                  85.82%

                  5% / Insider Ownership

                  1.00%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Oppenheimer Global Opportunities

                  •  

                    7,000,000

                  • 0.00

                  • 3.18

                  • SPDR® S&P Biotech ETF

                  •  

                    4,251,651

                  • 0.60

                  • 1.85

                  • Vanguard Small Cap Index

                  •  

                    3,820,654

                  • -0.22

                  • 1.74

                  • Vanguard Total Stock Mkt Idx

                  •  

                    3,605,580

                  • 0.17

                  • 1.64

                  • iShares Russell 2000 (AU)

                  •  

                    3,447,694

                  • -1.01

                  • 1.50

                  • iShares Nasdaq Biotechnology

                  •  

                    2,938,692

                  • 3.08

                  • 1.28

                  • PowerShares Dynamic Biotech&Genome Port

                  •  

                    2,669,924

                  • 0.00

                  • 1.16

                  • Vanguard Small Cap Growth Index Fund

                  •  

                    2,580,804

                  • -2.08

                  • 1.17

                  • Vanguard Extended Market Index Fund

                  •  

                    2,075,123

                  • 1.47

                  • 0.94

                  • iShares Russell 2000 Growth

                  •  

                    1,611,113

                  • 0.77

                  • 0.70

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Wellington Management Company, LLP

                  •  

                    27,893,387

                  • +1.25%

                  • 12.70

                  • Vanguard Group, Inc.

                  •  

                    13,343,977

                  • 0.00%

                  • 6.08

                  • BlackRock Fund Advisors

                  •  

                    7,730,062

                  • -7.81%

                  • 3.52

                  • OppenheimerFunds, Inc.

                  •  

                    7,000,000

                  • 0.00%

                  • 3.19

                  • State Street Corp

                  •  

                    6,637,729

                  • -7.88%

                  • 3.02

                  • Deerfield Management Co

                  •  

                    4,369,066

                  • +259.13%

                  • 1.99

                  • Susquehanna Financial Group, LLLP

                  •  

                    3,967,695

                  • +10.14%

                  • 1.81

                  • Northern Trust Investments, N.A.

                  •  

                    2,582,512

                  • -10.74%

                  • 1.18

                  • Morgan Stanley & Co Inc

                  •  

                    1,880,346

                  • +406.96%

                  • 0.86

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Arena Pharmaceuticals, Inc., was incorporated in the state of Delaware in April 14, 1997, and commenced operations in July 1997. The Company is a clinical-stage biopharmaceutical company engaged in discovering, developing and commerc...moreializing oral drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ, its internally discovered drug for chronic weight management in adults who are overweight with a comorbidity or obese, is its first and only drug approved for marketing by any regulatory agency. In June 2012, the U.S. Food and Drug Administration, or FDA, approved its internally discovered drug, BELVIQ, for chronic weight management in adults who are overweight with comorbidity or obese. The Company is engaged in commercializing BELVIQ in the United States and u...moreltimately in additional territories, selectively advancing its drug candidates and discovering additional drug candidates. Its programs include: BELVIQ, for chronic weight management; APD811, an orally available agonist of the prostacyclin (IP) receptor, is an internally discovered investigational drug candidate intended for the treatment of Pulmonary Arterial Hypertension; Temanogrel, an orally available inverse agonist of the serotonin 2A receptor, is an internally discovered investigational drug candidate intended for the treatment of thrombotic diseases; APD334, an orally available agonist of the S1P1 receptor, is an internally discovered investigational drug candidate intended for the potential treatment of a number of conditions related to autoimmune diseases, including multiple sclerosis, psoriasis and rheumatoid arthritis; APD371, an orally available agonist of the cannabinoid 2 receptor, is an internally discovered investigational drug candidate intended for the treatment of pain; GPR119, represents pharmaceutical target for discovering orally available small molecule agonists for the treatment of type 2 diabetes. The Company’s wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH, granted Eisai Inc., and Eisai Inc.'s parent company, Eisai Co. Ltd. exclusive rights to commercialize BELVIQ in the United States. The Company competes successfully against these organizations, which include many large, well-financed and experienced pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company's research and development programs involve the controlled use of hazardous materials, chemicals, biological materials and various radioactive compounds. In the United States, the Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, US Environmental Protection Agency, California Environmental Protection Agency, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the CSA and other federal, state or local regulations.lessless

                  Key People

                  Jack Lief

                  CEO/Chairman of the Board/Co-Founder/Director/President

                  Dr. Dominic P. Behan,PhD

                  Chief Scientific Officer/Co-Founder/Director/Executive VP

                  Robert E. Hoffman,C.P.A.

                  CFO/Chief Accounting Officer/Senior VP, Divisional

                  Steven W. Spector,J.D.

                  Executive VP/General Counsel/Secretary

                  Dr. Harry F. Hixson

                  Director

                  • Arena Pharmaceuticals Inc

                  • 6154 Nancy Ridge Drive

                  • San Diego, CA 92121

                  • USA.Map

                  • Phone: +1 858 453-7200

                  • Fax: +1 858 453-7210

                  • arenapharm.com

                  Incorporated

                  1997

                  Employees

                  310

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: